Biomed Pharmaceuticals Names New CEO
Gaston L. Bernstein Appointed Chief Executive Officer of Biomed Pharmaceuticals
SHARON HILL, Pa.--(BUSINESS WIRE)--Biomed Pharmaceuticals, (“Biomed” or the “Company”), a leading national pharmacy provider of intravenous and injectable medications for patients with chronic disorders, has named Gaston L. Bernstein as Chief Executive Officer of Biomed effective immediately. Mr. Bernstein has also been elected to Biomed’s board of directors. Most recently, Mr. Bernstein spent seven years at Coram Specialty Infusion Services, the pharmacy division of Apria Healthcare, a $2.3 billion home healthcare company.
“We welcome Gaston to the Biomed team and look forward to the continued growth of the Company. Gaston brings a wealth of specialty pharmacy industry experience which he has gained in his 22 years of working in the healthcare industry”
At Coram, Mr. Bernstein was the Corporate Vice President of Industry Relations, responsible for business development and relationships with pharmaceutical manufacturers. Prior to that, Mr. Bernstein was the Vice President and General Manager of CoramRx Specialty Pharmacy, which he successfully led to improved growth and profitability. Mr. Bernstein has an undergraduate degree in Molecular Biology and Biochemistry from the University of California at Irvine and an MBA from the University of Southern California.
“The opportunity to contribute to the growth of an organization with a relentless focus on delivering the highest quality service to all patients, referral sources, payers and manufacturers is very gratifying to me. We will continue to make this the cornerstone of our business while growing our specialty pharmacy service offerings and geographic markets which we serve from our six pharmacies from coast to coast. It’s very exciting to be joining the Biomed team,” remarked Bernstein.
“We welcome Gaston to the Biomed team and look forward to the continued growth of the Company. Gaston brings a wealth of specialty pharmacy industry experience which he has gained in his 22 years of working in the healthcare industry,” commented Brian Schwartz, Biomed Director and Executive Managing Director at H.I.G. Capital, whose affiliate is the majority shareholder of the Company.
About Biomed Pharmaceuticals
The Company is a leading pharmacy provider of intravenous and injectable medications for patients with chronic disorders. Biomed treats a variety of immune deficient and autoimmune disorders through Intravenous Immunoglobulin (“IVIG”) therapy, as well as hemophilia and Rheumatoid Arthritis. In addition to filling a patient’s prescriptions, Biomed’s specialized nurses infuse medications and assist with standardized therapy specific education. Through its ACHC accredited and strategically located pharmacies, Biomed serves patients in over 30 states across the U.S. Visit www.biomed-rx.com.